These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 32521564)
21. DISEASES OF THE ORAL MUCOSA IN PATIENTS IN THE POST-COVID PERIOD. Kamilov K; Kadirbaeva A; Rakhimova M; Lukina G; Abramova M; Lukin A; Alimova A Georgian Med News; 2022; (328-329):127-132. PubMed ID: 36318856 [TBL] [Abstract][Full Text] [Related]
22. Oral manifestations in a patient with a history of asymptomatic COVID-19: Case report. Corchuelo J; Ulloa FC Int J Infect Dis; 2020 Nov; 100():154-157. PubMed ID: 32882435 [TBL] [Abstract][Full Text] [Related]
23. Histopathology of cutaneous COVID-19 lesion: possible SARS-CoV-2 cytopathogenic effect. Drak Alsibai K; Michaud C; Taquet A; Demar M; Blaizot R Pathology; 2020 Dec; 52(7):816-818. PubMed ID: 32863022 [No Abstract] [Full Text] [Related]
24. Mucosal involvement in a COVID-19-positive patient: A case report. Cebeci Kahraman F; Çaşkurlu H Dermatol Ther; 2020 Jul; 33(4):e13797. PubMed ID: 32520428 [No Abstract] [Full Text] [Related]
25. Could mouth rinses be an adjuvant in the treatment of SARS-CoV-2 patients? An appraisal with a systematic review. Gandhi G; Thimmappa L; Upadhya N; Carnelio S Int J Dent Hyg; 2022 Feb; 20(1):136-144. PubMed ID: 34628705 [TBL] [Abstract][Full Text] [Related]
26. Case report of oral mucosa garlic burn during COVID-19 pandemic outbreak and role of teledentistry to manage oral health in an older adult woman. Muniz IAF; Campos DES; Shinkai RSA; Trindade TGD; Cosme-Trindade DC Spec Care Dentist; 2021 Sep; 41(5):639-643. PubMed ID: 34029421 [TBL] [Abstract][Full Text] [Related]
27. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. Tammaro A; Adebanjo GAR; Parisella FR; Pezzuto A; Rello J J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):e306-e307. PubMed ID: 32330340 [No Abstract] [Full Text] [Related]
28. COVID-19 Pandemic: Are There Unique Cutaneous Manifestations in Patients Infected With SARS-CoV-2? Wei C; Friedman AJ J Drugs Dermatol; 2020 May; 19(5):554-555. PubMed ID: 32484624 [No Abstract] [Full Text] [Related]
29. Oral mucosal lesions in patients with SARS-CoV-2 infection. Report of four cases. Are they a true sign of COVID-19 disease? Cruz Tapia RO; Peraza Labrador AJ; Guimaraes DM; Matos Valdez LH Spec Care Dentist; 2020 Nov; 40(6):555-560. PubMed ID: 32882068 [TBL] [Abstract][Full Text] [Related]
30. Skin manifestations during the COVID-19 pandemic in the pediatric emergency department. Oliva Rodríguez-Pastor S; Martín Pedraz L; Carazo Gallego B; Galindo Zavala R; Lozano Sánchez G; de Toro Peinado I; Rodriguez Benjumea M; Mejias A; Núñez Cuadros E Pediatr Int; 2021 Sep; 63(9):1033-1037. PubMed ID: 33278056 [TBL] [Abstract][Full Text] [Related]
31. Dermatologic treatments in the era of COVID-19 pandemic-Data and Hypothesis. Sadoughifar R; Goldust M; Kroumpouzos G; Szepietowski JC; Lotti T; Sandhu S Dermatol Ther; 2020 Jul; 33(4):e13562. PubMed ID: 32396251 [No Abstract] [Full Text] [Related]
32. Altitude and SARS-CoV-2 Infection in the First Pandemic Wave in Spain. Castilla J; Fresán U; Trobajo-Sanmartín C; Guevara M Int J Environ Res Public Health; 2021 Mar; 18(5):. PubMed ID: 33806642 [TBL] [Abstract][Full Text] [Related]
33. Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration. Ghazawi FM; Lim M; Dutz JP; Kirchhof MG Int J Dermatol; 2020 Sep; 59(9):1043-1056. PubMed ID: 32621284 [TBL] [Abstract][Full Text] [Related]
34. The Impact of COVID-19 on the Life Quality of Ambulatory Patients With Chronic Skin Conditions. Plachouri KM; Georgiou S J Ambul Care Manage; 2021; 44(1):85-86. PubMed ID: 33165123 [TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Colmenero I; Santonja C; Alonso-Riaño M; Noguera-Morel L; Hernández-Martín A; Andina D; Wiesner T; Rodríguez-Peralto JL; Requena L; Torrelo A Br J Dermatol; 2020 Oct; 183(4):729-737. PubMed ID: 32562567 [TBL] [Abstract][Full Text] [Related]
36. A Concept for the Reduction of Mucosal SARS-CoV-2 Load using Hypochloric Acid Solutions. Mueller CA; Winter M; Renner B Drug Res (Stuttg); 2021 Jul; 71(6):348-350. PubMed ID: 33890267 [TBL] [Abstract][Full Text] [Related]
37. Palliative psychodermatology care during COVID-19 pandemic. Hafi B; Uvais NA; Jafferany M; Afra TP; Muhammed RT Dermatol Ther; 2020 Jul; 33(4):e13732. PubMed ID: 32473043 [No Abstract] [Full Text] [Related]
38. [COVID-19 in Spain: the psychological impact of the pandemic on nurses]. Fernández VÁ; Bouchard JP Rev Infirm; 2020 Oct; 69(264):33-35. PubMed ID: 33129475 [TBL] [Abstract][Full Text] [Related]
39. Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensus-based guidance for clinical decision-making during the COVID-19 pandemic. Reynolds SD; Mathur AN; Chiu YE; Brandling-Bennett HA; Pope E; Siegel MP; Holland KE; Paller AS; Siegfried EC; Tom WL; Lara-Corrales I; Tollefson MM; Maguiness S; Eichenfield LF; Sugarman J; Frieden IJ; Oza VS; Cipriano SD; Huang JT; Shah SD; Lauren CT; Castelo-Soccio L; McMahon P; Cordoro KM Pediatr Dermatol; 2020 May; 37(3):424-434. PubMed ID: 32320494 [TBL] [Abstract][Full Text] [Related]
40. Association of skin diseases, biological treatment and COVID-19 during the first wave of the pandemic. Descalzo MA; Garcia-Doval I Br J Dermatol; 2021 Feb; 184(2):194. PubMed ID: 33274755 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]